Immunotherapy provides long-term survival benefit: Further evidence in lung cancer

0

(European Society for Medical Oncology) Further evidence that immunotherapy provides long-term survival benefit for patients with lung cancer was presented today at ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland.Researchers presented the three-year survival results of the randomised phase 2 POPLAR trial in second line, which is the longest follow-up reported to date with anti-programmed death ligand 1 (PD-L1) immunotherapy in patients with previously treated, advanced non-small-cell lung cancer (NSCLC).

Leave A Reply

Your email address will not be published.